FibroGen lays off 75% of US staff as cancer drug flunks 2 more trials

FibroGen is radically restructuring its business, laying off 75% of its U.S. staff and stopping investment in its lead candidate in response to the failure of two late-phase pancreatic cancer clinical trials.